Previous 10 | Next 10 |
2023-08-21 07:31:33 ET More on Krystal Biotech Krystal Biotech: Pioneering Rare Disease Gene Therapies Seeking Alpha’s Quant Rating on Krystal Biotech Earnings data for Krystal Biotech For further details see: Krystal Biotech announces sale of prio...
PITTSBURGH, Aug. 21, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (NASDAQ: KRYS) (the “Company”), a commercial-stage biotechnology company focused on the discovery, development, and commercialization of genetic medicines to treat diseases with high unmet medical needs, announced t...
2023-08-07 07:18:11 ET Krystal Biotech press release ( NASDAQ: KRYS ): Q2 GAAP EPS of -$1.25 misses by $0.51 . Cash, cash equivalents, and investments totaled $505.9 million on June 30, 2023. For further details see: Krystal Biotech GAAP EPS of -$1.25 mi...
• VYJUVEK™ approved in the U.S. as the first and only topical redosable gene therapy for the treatment of dystrophic epidermolysis bullosa • 121 Patient Start Forms in the first six weeks of launch • First cystic fibrosis patient dosed in Phase 1...
2023-07-31 22:26:21 ET Summary Krystal Biotech's FDA-approved gene therapy for DEB sets a medical milestone, opening new revenue streams. With a robust financial health, Krystal prepares to launch a diverse pipeline of innovative gene therapies. Despite potential rewards, risi...
PITTSBURGH, July 26, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company focused on the discovery, development and commercialization of genetic medicines to treat diseases with high unmet medical needs, anno...
2023-07-21 08:15:00 ET Investors looking for stocks with explosive growth potential would do well to take a gander at the biotech industry. Clinical and regulatory wins can fuel excellent stock market performances for companies in the sector in a relatively short period, say a year. But sho...
PITTSBURGH, July 03, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a biotechnology company focused on developing and commercializing genetic medicines for patients with debilitating diseases, announced today that the first patient has been do...
Krystal Biotech, Inc. (NASDAQ: KRYS) is the focus of IBN's latest stock spotlight. The company's shares have moved 0.59% on the day to $128.12. Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the Un...
PITTSBURGH, June 05, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) a biotechnology company focused on developing and commercializing genetic medicines for patients with rare diseases, announced today that the Company will participate in the fo...
News, Short Squeeze, Breakout and More Instantly...
PITTSBURGH, July 26, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that it will report its second quarter 2024 financial results on Monday, August 5, 2024, prior to the open of U....
A look at the top 10 most actives in the United States Serve Robotics Inc. (SERV) rose 187.1% to $7.55 on volume of 255,453,115 shares 60 Degrees Pharmaceuticals Inc. (SXTP) rose 10.2% to $0.271 on volume of 224,640,171 shares NVIDIA Corporation (NVDA) fell 2.6% to $117.93 on volume of 21...
A look at the top 10 most actives in the United States 60 Degrees Pharmaceuticals Inc. (SXTP) rose 98.3% to $0.4878 on volume of 116,444,604 shares NVIDIA Corporation (NVDA) fell 0.2% to $120.8 on volume of 26,900,560 shares Serve Robotics Inc. (SERV) rose 61.2% to $4.2399 on volume of 25...